Search This Blog

Thursday, May 22, 2025

Biodexa Additional $3.0M Grant from CPRIT for Registrational eRapa Phase 3

Biodexa Pharmaceuticals (NASDAQ: BDRX) has announced that its partner Emtora Biosciences received an additional $3.0 million grant from the Cancer Prevention & Research Institute of Texas (CPRIT) to support their Phase 3 program of eRapa in familial adenomatous polyposis (FAP). This brings the total CPRIT funding to $20.0 million for the program. The Phase 3 study will be a double-blind placebo-controlled trial involving 168 patients, randomized 2:1 drug/placebo, across approximately 30 clinical sites in the US and Europe. The study is in its final implementation stages, with recruitment expected to begin in the coming weeks. The US component will be conducted by LumaBridge, while Precision for Medicine LLC will handle the European component.

No comments:

Post a Comment

Note: Only a member of this blog may post a comment.